Self-Expandable Stents

Global Self-Expandable Stents Market to Reach US$5.4 Billion by 2030

The global market for Self-Expandable Stents estimated at US$3.6 Billion in the year 2024, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Carotid Self-Expanding Stents, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Gastrointestinal Self-Expanding Stents segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$977.6 Million While China is Forecast to Grow at 11.2% CAGR

The Self-Expandable Stents market in the U.S. is estimated at US$977.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Self-Expandable Stents Market - Key Trends & Drivers Summarized

Why Are Self-Expandable Stents Emerging as a Preferred Option in Minimally Invasive Interventions?
Self-expandable stents are gaining widespread adoption in cardiovascular, neurovascular, and peripheral artery disease treatments due to their superior conformability, radial strength, and adaptability in tortuous anatomies. Constructed primarily from shape-memory alloys like nitinol, these stents expand automatically upon deployment and adapt to vessel dynamics, making them ideal for locations where vessel movement or size variability is a concern. Unlike balloon-expandable stents, self-expandable versions exert continuous outward pressure, providing long-term vessel patency in stenotic or occluded regions and minimizing the risk of restenosis.

In peripheral vascular interventions-such as in the femoropopliteal or iliac arteries-self-expandable stents have shown better outcomes due to their flexibility and resistance to mechanical fatigue from limb movement. In carotid artery and neurovascular procedures, their ability to accommodate dynamic vascular motion while preserving flow in adjacent branches makes them especially useful in complex lesion morphologies. The trend toward transcatheter and endovascular procedures over open surgery is reinforcing the demand for stents that can be delivered via small-diameter sheaths with high precision and minimal trauma, positioning self-expandable designs as integral to next-generation interventional therapies.

How Are Material Science and Design Advancements Improving Clinical Outcomes?
Material innovation is a key driver of performance improvements in self-expandable stents. Nitinol, with its thermal memory and superelastic properties, remains the material of choice, but newer stents are incorporating enhanced coatings, dual-layer designs, and radiopaque markers for improved visibility, biocompatibility, and endothelialization. Drug-eluting self-expandable stents are being developed to combine mechanical support with localized drug delivery, especially in patients with high restenosis risk. These stents use antiproliferative agents like paclitaxel or sirolimus to reduce neointimal hyperplasia, with biodegradable polymer coatings ensuring controlled drug release and minimized long-term inflammation.

Advanced braiding and laser-cut designs are allowing for precise expansion, greater side-branch preservation, and reduced foreshortening, critical for stent placement in bifurcated or aneurysmal vessels. In neurointervention, flow-diverter stents that reduce aneurysmal blood flow and promote remodeling are incorporating self-expanding frameworks to enhance navigability through tortuous cerebral vasculature. Manufacturers are also focusing on dual-layer stent architectures for embolic protection during carotid interventions, reducing stroke risk. These design refinements are enhancing deliverability, deployment accuracy, and long-term efficacy-thereby supporting regulatory approvals and broader clinical acceptance.

Which Clinical Applications and Geographies Are Driving Market Penetration?
The global burden of chronic vascular diseases-such as peripheral artery disease (PAD), coronary artery disease (CAD), and cerebrovascular diseases-is fueling procedural volume for stent-based interventions. Aging populations, rising diabetes prevalence, and lifestyle-related cardiovascular risks are expanding the target patient base, particularly in North America, Western Europe, and Asia-Pacific. In regions like India, China, and Brazil, healthcare access improvements and government investments in cath labs are boosting stent uptake across both public and private health systems.

Neurovascular applications are showing rapid growth, especially in stroke prevention and aneurysm treatment, where minimally invasive access is critical. The increasing use of carotid artery stenting in patients with surgical contraindications is also driving demand for self-expandable devices. In gastrointestinal and urological segments, self-expanding stents are being used for the palliative treatment of malignant obstructions (e.g., esophageal, biliary, and ureteral stenting), enabling non-surgical decompression in cancer patients. Emerging economies are adopting cost-effective generic stents, while developed markets are favoring premium drug-eluting or specialized designs based on clinical sophistication.

What Is Driving Global Demand for Self-Expandable Stents Across Clinical Segments?
The growth in the self-expandable stents market is driven by several factors, including the increasing preference for minimally invasive therapies, technological innovation, and expanding disease prevalence across demographic groups. As procedural guidelines evolve to favor endovascular approaches over open surgery-backed by real-world evidence and trial data-self-expandable stents are being positioned as first-line devices in various vascular and non-vascular indications. Patient preference for faster recovery, reduced hospitalization, and lower procedural risk is reinforcing this transition.

R&D efforts are yielding devices tailored to highly specific anatomical and pathological scenarios, supporting more personalized intervention strategies. Reimbursement expansion and approval of newer drug-eluting models are further catalyzing market uptake, particularly in OECD countries. Strategic collaborations between medical device companies and interventional radiology centers are accelerating innovation cycles, clinical validation, and market reach. Regulatory support for expedited approvals under breakthrough designation or equivalence pathways is also enabling quicker access to cutting-edge stent technologies.

With a favorable convergence of clinical need, procedural trends, and material innovation, the self-expandable stents market is set for sustained growth. As endovascular therapies continue to advance and expand into new anatomical territories, self-expanding stent technologies will remain central to improving long-term patient outcomes across global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Self-Expandable Stents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Carotid Self-Expanding Stents, Gastrointestinal Self-Expanding Stents, Endovascular Self-Expandable Stents, Other Product Types); Application (Fem-Pop Artery Application, Iliac Artery Application, Carotid Artery Application, Biliary Application, Other Applications); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Abbott Laboratories
• Acandis GmbH
• AMG International GmbH
• B. Braun Melsungen AG
• Becton, Dickinson and Co.
• Biosensors International
• Biotronik
• Boston Scientific
• Cook Medical
• Cordis
• Endologix LLC
• InspireMD
• JOTEC GmbH
• Lepu Medical
• Medtronic plc
• MicroPort Scientific Corp
• Stryker Corporation
• Terumo Corporation
• Translumina Therapeutics
• W. L. Gore & Associates

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more